Abstract
BackgroundGiACTA, a randomized, double-blind, placebo-controlled trial, evaluated the efficacy and safety of tocilizumab (TCZ), an IL-6 receptor-α inhibitor, in patients with giant cell arteritis (GCA).1,2ObjectivesSecondary analyses to evaluate the differential...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have